Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | ITGB2 | P05107 | 11/20 | 0.43 |
| ▸ | ICAM1 | P05362 | 11/20 | 0.43 |
| ▸ | ITGAL | P20701 | 11/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.41 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.41 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30083856 | 1.00 | MAPT (0.48) | MAPTTDP1ITGB2ICAM1ITGAL | |
| SCHEMBL24803375 | 1.00 | MAPT (0.48) | MAPTTDP1ITGB2ICAM1ITGAL | |
| SCHEMBL24803486 | 0.96 | EPHX2 (0.43) | MAPTTDP1ITGB2ICAM1ITGAL | |
| SCHEMBL30083840 | 0.96 | EPHX2 (0.43) | MAPTTDP1ITGB2ICAM1ITGAL | |
| SCHEMBL24805463 | 0.96 | EPHX2 (0.43) | MAPTTDP1ITGB2ICAM1ITGAL | |
| SCHEMBL24803177 | 0.90 | ITGB2 (0.53) | ITGB2ICAM1ITGALTAS1R3TAS1R1 | |
| SCHEMBL29019152 | 0.90 | ITGB2 (0.53) | ITGB2ICAM1ITGALTAS1R3TAS1R1 | |
| SCHEMBL23978606 | 0.90 | ITGB2 (0.53) | ITGB2ICAM1ITGALTAS1R3TAS1R1 | |
| SCHEMBL23978729 | 0.90 | ITGB2 (0.53) | ITGB2ICAM1ITGALTAS1R3TAS1R1 | |
| SCHEMBL30083837 | 0.90 | ITGB2 (0.53) | ITGB2ICAM1ITGALTAS1R3TAS1R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11643388-B2 | Inhibitors of alpha 2 beta 1 integrin and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-05-09 | — | — | US | disclosed |
| WO-2021222789-A1 | INHIBITORS OF ALPHA 2 BETA 1 INTEGRIN AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11643388-B2 | Inhibitors of alpha 2 beta 1 integrin and methods of use thereof | ITGB1, ITGB2, ITGA2 | MAPT 4656/4885TDP1 2994/4885ITGB2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.